Psychedelic News and Analysis Made Simple for Investors
Psychedelic Invest is a resource for those looking to invest in the burgeoning psychedelic industry.
Track the entire psychedelic market
We’ve developed the first all encompassing index to track the public psychedelic marketplace.
Explore the Index
Just Some of the Data we Cover
Latest News
Lifestyle
May 7
•
2 min read
Oprah’s website OprahDaily.com has published a guide to psychedelics and psychedelic-assisted therapy. The inclusion of a comprehensive guide to psychedelics on Oprah Daily marks a significant turning point for the psychedelics industry. This initiative not only elevates the conversation around psychedelic therapy into mainstream discourse but also reflects the growing acceptance and curiosity surrounding these…
Lifestyle
I grew up on the internet. Along the way, I became a fan of the Onion. For those that are unfamiliar, the Onion is a hilarious satirical zine that come up with the most outrageous stories to garner as many laughs as possible. While The Onion has been on my radar in 15 years, I…
May 7
•
2 min read
Press
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today presented data from MMED008, its Phase 2b study of MM120 (lysergide d-tartrate) in the treatment of GAD in adults. MM120 demonstrated clinically and statistically significant efficacy compared to placebo at its…
May 6
•
7 min read
Press
NAPANEE, Ontario, May 06, 2024 (GLOBE NEWSWIRE) — Lophos Holdings Inc. (“Lophos”, or the “Company”) (CSE:MESC) is pleased to announce that its wholly-owned subsidiary, Lophos Pharmaceuticals Corp. (“Lophos Pharma”) – a biosciences company specializing in the cultivation, research, and sale of Lophophora williamsii (peyote), announced today that it has entered into a letter of intent to acquire the cactus cultivation business…
May 6
•
3 min read
Press
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, provides a corporate update highlighting recent clinical accomplishments and key upcoming catalysts across its development pipeline. “With the prevalence and burden of mental health conditions at an all-time…
May 6
•
5 min read
Press
VANCOUVER – MindBio Therapeutics Corp. (CSE: MBIO) (Frankfurt: WF6), (the ‘Company’ or ‘MindBio’), a clinical stage biopharma company pioneering microdosing treatments for mental health conditions showcases Dr Rachael Sumner, presenting MindBio’s landmark women’s health trials. The trials in women’s health aim to address a huge unmet need in effectively treating Pre-Menstrual Syndrome (PMS) and Pre-Menstrual Dysphoric disorder (PMDD) without…
May 3
•
3 min read
Press
TORONTO, May 03, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it has officially launched its Prescribers Portal for medical practitioners with…
May 3
•
3 min read
Explore the Psychedelic Landscape
Learn more about the psychedelic companies changing the industry.